8-K: Codexis Reports First Quarter 2025 Financial Results, Reaffirms Full-Year Guidance

Codexis announced its Q1 2025 financial results, highlighting its first revenue-generating contract for ECO Synthesis manufacturing services and reiterating its full-year financial guidance.

Summary

• Codexis announced its financial results for the first quarter ended March 31, 2025.
• The company secured its first revenue-generating contract for ECO Synthesis manufacturing services.
• Codexis reiterated its full-year financial guidance.
• First quarter total revenues were $7.5 million, compared to $17.1 million in the first quarter of 2024.
• The decrease in revenue was primarily due to a $6.0 million revenue recognition from a licensing agreement with Roche in Q1 2024 and two sizable customer orders placed in the first quarter of 2024.
• Product gross margin was 55% for the first quarter of 2025, compared to 49% in the first quarter of 2024.
• The net loss for the first quarter of 2025 was $20.7 million, or $0.25 per share, compared to a net loss of $11.5 million, or $0.16 per share, for the first quarter of 2024.
• As of March 31, 2025, the company had $59.8 million in cash, cash equivalents, and short-term investments.
• Codexis expects total revenues for 2025 to be in the range of $64 million to $68 million.
• The company anticipates achieving cash flow positivity by the end of 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue and net loss figures are worse than the previous year, the company secured a key contract, reiterated its full-year guidance, and expects to achieve cash flow positivity by the end of 2026. The delay of a $2.5 million order and increased net loss temper the positive aspects.

Positives

• Codexis secured its first revenue-generating contract for ECO Synthesis manufacturing services.
• Product gross margin increased to 55% in Q1 2025 from 49% in Q1 2024.
• The company reiterated its full-year 2025 financial guidance, projecting revenues between $64 million and $68 million.
• Codexis expects to achieve cash flow positivity by the end of 2026.
• Codexis finished the first quarter with $60 million in cash.
• The company successfully completed development of the first generation of its core ECO Synthesis enzymes.
• The ligase business is gaining traction, with new orders from large pharma customers.

Negatives

• Total revenues decreased to $7.5 million in Q1 2025 from $17.1 million in Q1 2024.
• The net loss increased to $20.7 million in Q1 2025 from $11.5 million in Q1 2024.
• A $2.5 million customer order was delayed from Q1 to Q2.

Risks

• Codexis depends on its licensees and collaborators.
• The company may need additional capital in the future.
• Codexis depends on a limited number of products and customers.
• The company's ability to accurately forecast financial and operational performance is a risk.
• Market, political, and economic conditions may negatively impact Codexis' business, financial condition, and share price.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect the business.

Future Outlook

Codexis expects total revenues for 2025 to be in the range of $64 million to $68 million and anticipates achieving cash flow positivity by the end of 2026.

Management Comments

• Codexis finished the first quarter with $60 million in cash, which remains on track to fund the company through cash flow positivity by the end of 2026, said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis.
• We delivered a solid performance this quarter, despite the slip of a $2.5 million customer order from Q1 to Q2, said Georgia Erbez, Chief Financial Officer of Codexis.
• As we've highlighted in the past, our revenue can be unpredictable as large orders such as this one can be delayed by a customer by only a few weeks, said Georgia Erbez, Chief Financial Officer of Codexis.

Industry Context

Codexis is operating in the enzymatic solutions market for therapeutics manufacturing, particularly in the growing field of RNAi therapeutics. The company's ECO Synthesis platform aims to capitalize on the increasing demand for efficient and scalable manufacturing solutions in this space, aligning with the broader trend of building U.S.-based manufacturing infrastructures.

Comparison to Industry Standards

• Codexis is positioning itself to compete with companies like Thermo Fisher Scientific and Danaher in the enzyme and nucleic acid synthesis market.
• The ECO Synthesis platform is aimed at competing with traditional chemical synthesis methods for RNAi therapeutics, offering a potentially more sustainable and efficient alternative.
• The company's focus on enzymatic solutions aligns with the industry's move towards greener and more sustainable manufacturing processes, similar to initiatives seen at companies like Amyris and Novozymes.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and future outlook will impact shareholder value.
• Employees: The company's performance and strategic direction will affect employee morale and job security.
• Customers: The development of the ECO Synthesis platform and enzymatic solutions will impact the efficiency and scalability of therapeutics manufacturing for customers.
• Suppliers: The company's operations and growth will influence demand for supplies and services.
• Creditors: The company's financial stability and ability to meet debt obligations will affect creditors.

Next Steps

• Codexis will host two oral presentations and one poster at the 2025 TIDES USA annual meeting from May 19-22, 2025.
• The company expects to achieve pilot scale production of GLP-grade siRNA material using the ECO Synthesis Innovation Lab in 2025.
• Codexis expects to sign a GMP scale-up partner by the end of 2025 to enable larger scale clinical and commercial siRNA production.

Key Dates

Keywords

Codexis, financial results, ECO Synthesis, enzymes, RNAi therapeutics, biocatalysis, ligase, siRNA, manufacturing, revenue, gross margin, net loss